2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Stomach Neoplasms
8
Lymphoma, B-Cell, Marginal Zone
5
Gastritis
5
Lymphoma
4
Dyspepsia
4
Peptic Ulcer
3
Neoplasms
2
Stomach Ulcer
1
Skin Neoplasms
1
Pseudomyxoma Peritonei
1
Precancerous Gastric Lesions
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Helicobacter Infections
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer
1
Fever
1
Familial primary gastric lymphoma
1
Drug-Related Side Effects and Adverse Reactions
1
Cystectomy
1
Chemotherapy Effect
1
Brain Neoplasms
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
9
Ciprofloxacin
8
Voriconazole
5
Vancomycin
4
Caspofungin
4
Amoxicillin-Potassium Clavulanate Combination
4
gamma-Globulins
3
Fluconazole
3
Filgrastim
3
Daptomycin
3
Antibiotic Prophylaxis
3
plerixafor
2
liposomal amphotericin B
2
Whole-Body Irradiation
2
Trimethoprim
2
Therapeutics
2
Sulfamethoxazole
2
Saline Solution
2
Ribavirin
2
Polymerase Chain Reaction
2
Piperacillin, Tazobactam Drug Combination
2
Peripheral Blood Stem Cell Transplantation
2
Pentetic Acid
2
Moxifloxacin
2
Melphalan
2
Levofloxacin
2
Lenalidomide
2
Itraconazole
2
Immunoglobulins, Intravenous
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Infections
×
Amoxicillin
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled